Literature DB >> 20181964

The FDA and safe use of long-acting beta-agonists in the treatment of asthma.

Badrul A Chowdhury1, Gerald Dal Pan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20181964     DOI： 10.1056/NEJMp1002074

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  59 in total

1.  Beta-agonist-associated reduction in RGS5 expression promotes airway smooth muscle hyper-responsiveness.

Authors:  Zhao Yang; Philip R Cooper; Gautam Damera; Indranil Mukhopadhyay; Hyeseon Cho; John H Kehrl; Reynold A Panettieri; Kirk M Druey
Journal:  J Biol Chem       Date:  2011-01-29       Impact factor: 5.157

2.  The relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population.

Authors:  Karen E Wells; Edward L Peterson; Brian K Ahmedani; Richard K Severson; Julie Gleason-Comstock; L Keoki Williams
Journal:  J Allergy Clin Immunol       Date:  2012-01-26       Impact factor: 10.793

Review 3.  The risks of risk aversion in drug regulation.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Daniel Brasseur; Alasdair Breckenridge; Hubert Leufkens; June Raine; Tomas Salmonson; Christian K Schneider; Guido Rasi
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

4.  Update in asthma 2010.

Authors:  Shamsah Kazani; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2011-08-01       Impact factor: 21.405

Review 5.  β(2) -adrenoceptor agonists: current and future direction.

Authors:  Mario Cazzola; Luigino Calzetta; Maria Gabriella Matera
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 6.  Emerging issues in pediatric asthma: gaps in EPR-3 guidelines for infants and children.

Authors:  Daniel J Jackson
Journal:  Curr Allergy Asthma Rep       Date:  2014-12       Impact factor: 4.806

Review 7.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

Review 8.  Emerging role of long acting muscarinic antagonists for asthma.

Authors:  Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

9.  New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist.

Authors:  Emad A Koshak
Journal:  Ann Thorac Med       Date:  2010-04       Impact factor: 2.219

10.  Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.

Authors:  Jorge F Maspero; Hendrik Nolte; Iván Chérrez-Ojeda
Journal:  J Asthma       Date:  2010-11-01       Impact factor: 2.515
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.